Brief: Alkem Labs Signs Deal With Sonnet Biotherapeutics To Develop Diabetic Peripheral Neuropathy Drug
10/10/2024 09:34
Oct 10 (Reuters) - Alkem Laboratories Ltd ALKE.NS :
* SIGNED A LICENSING AGREEMENT WITH SONNET BIOTHERAPEUTICS
HOLDINGS
* SIGNS LICENSING AGREEMENT WITH SONNET BIOTHERAPEUTICS
HOLDINGS,
INC
* TO DEVELOP, COMMERCIALIZE 'SON-080' FOR TREATMENT OF
DIABETIC
PERIPHERAL NEUROPATHY
* ALKEM HAS EXCLUSIVE RIGHTS TO DEVELOP, MANUFACTURE AND
COMMERCIALISE DRUG IN INDIA
* CO TO CARRY OUT CLINICAL DEVELOPMENT OF "SON-080" IN INDIA
TO
ENABLE REGULATORY FILINGS
Source text for Eikon: ID:nBSE9MwnfJ
Further company coverage: ALKE.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alkem Laboratories
See all newsBrief: Alkem Labs Approved Initiation Of Forensic Audit In Connection With Recent Incident Involving Alleged Misappropriation Of Funds By A Former Employee
Brief: Alkem Labs Launches Neuceno (Cenobamate) For Treatment Of Partial-Onset Seizures In Adult Patients
Brief: Alkem Labs Launches Renocia Exo, Ginsenoside Exosome-Based Hair Growth Serum
Brief: Alkem Labs Board Approves Investment Of Up To 750 Million Rupees For New Block At Baddi Manufacturing Facility
Brief: Alkem Laboratories Q1 Consol Revenue From Operations 37.4 Billion Rupees